Jasper Therapeutics, Inc. announced the initiation of a Phase I/II clinical trial to evaluate JSP191, the company’s anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning agent prior to allogeneic transplant in patients with GATA2-related myelodysplastic syndromes.
[Jasper Therapeutics, Inc. (Business Wire, Inc.)]
7992332
{7992332:nan}
apa
50
1
166502
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
